Antimigren (sumatriptan) tablets 100 mg. №1


Manufacturer: Ukraine

Antimigren (sumatriptan) tablets are prescribed for the rapid relief of migraine attacks, with or without aura. Antimigren (sumatriptan) tablets are used only with a clearly established diagnosis of migraine.




active ingredient: sumatriptan;

1 tablet contains sumatriptan 100 mg;

excipients: lactose monohydrate, povidone, microcrystalline cellulose calcium croscarmellose sodium stearate; silicon dioxide colloidal titanium dioxide (E 171) hypromellose.

Dosage form

Film-coated tablets.

Basic physical and chemical properties: film-coated tablets, white with a yellowish tint.

Pharmacotherapeutic group

Drugs used to treat migraine. Selective serotonin 5HT1 receptor agonists. Sumatriptan. ATX code N02C C01.


Sumatriptan is a selective 5HT1 receptor agonist that does not affect other 5HT receptors. These receptors are found mainly in the cranial blood vessels. In experimental studies, it was found that sumatriptan has a selective vasoconstrictive effect on the vessels in the carotid artery system, but does not affect cerebral circulation. The carotid system supplies blood to extra- and intracranial tissues, such as the meninges. Due to the expansion of these vessels, a migraine develops. Additionally, experimental data have shown that sumatriptan inhibits the activity of the trigeminal nerve. These are two possible mechanisms through which sumatriptan antimigraine activity is detected. The clinical effect is observed 30 minutes after taking 100 mg of the drug.


After oral administration, sumatriptan is rapidly absorbed, reaching 70% of the maximum concentration after 45 minutes. After taking 100 mg, the average maximum plasma concentration is 45 ng / ml. Bioavailability after oral administration is 14%, partly due to first pass metabolism, partly as a result of incomplete absorption. Plasma protein binding is low (14-21%), the average volume of distribution is 17 liters. The mean total clearance is approximately 1160 ml/min and the mean renal clearance is approximately 260 ml/min. Non-renal clearance is approximately 80% of total clearance, which suggests that sumatriptan is excreted mainly as metabolites. The main metabolite, the indolocytic analog of sumatriptan, is excreted in the urine, where it is found as a free acid and a glucuronide conjugate. It does not show 5HT1 and 5HT2 activities. Other metabolites have been identified. The pharmacokinetics of oral sumatriptan does not change significantly during a migraine attack.


Antimigren (sumatriptan) tablets are prescribed for the rapid relief of migraine attacks, with or without aura. Antimigren (sumatriptan) tablets are used only with a clearly established diagnosis of migraine.


Hypersensitivity to the components of the drug.

History of myocardial infarction, ischemic heart disease, Prinzmetal’s angina, peripheral vascular disease, or symptoms consistent with coronary artery disease.

History of stroke or transient cerebrovascular accident.

Moderate or severe hypertension and mild uncontrolled hypertension.

Severe liver failure.

Simultaneous use of ergotamine or its derivatives (including methysergide).

Simultaneous use of any triptan / 5-hydroxytryptamine receptor agonist (5-HT1).

Simultaneous use of monoamine oxidase inhibitors (MAO) and Antimigraine. Antimigren (sumatriptan) should not be used within 2 weeks after discontinuation of MAO inhibitors.

Dosage and administration

Antimigren (sumatriptan) tablets should not be used to prevent an attack.

The recommended doses of Antimigren (sumatriptan) should not be exceeded.

Antimigren (sumatriptan) is recommended to be used as early as possible after the onset of a migraine attack, although it is equally effective at each stage.

The recommended dose of Antimigren (sumatriptan) for adults is 50 mg. In some cases, the dose may be increased to 100 mg.

If a dose is ineffective, do not use another dose during the same attack. In such cases, paracetamol or acetylsalicylic acid or other non-steroidal anti-inflammatory drugs can be used. The next dose of Antimigren (sumatriptan) can be applied during the following attacks.

If the patient has responded to the first dose but symptoms recur, a second dose may be given within the next 24 hours, with a minimum interval of at least 2 hours between these doses. The total daily dose in any 24 hours should not exceed 300 mg.

Antimigren (sumatriptan) is prescribed as monotherapy for the rapid relief of migraine attacks and is not used simultaneously with ergotamine or its derivatives (including methysergide).

Tablets should be swallowed whole with water.

Elderly patients (over 65 years old)

There is insufficient experience with the use of sumatriptan in patients over 65 years of age. Although the pharmacokinetics of the drug does not differ from that in younger patients, until additional clinical data are obtained, the use of Antimigren (sumatriptan) in elderly patients is not recommended.